Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Cash (2016 - 2025)

Historic Change in Cash for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $17.4 million.

  • Spero Therapeutics' Change in Cash rose 3650.4% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year decrease of 5782.15%. This contributed to the annual value of -$23.4 million for FY2024, which is 2846.77% up from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Change in Cash is $17.4 million, which was up 3650.4% from -$17.7 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Change in Cash peaked at $58.7 million during Q4 2022, and registered a low of -$40.5 million during Q1 2022.
  • Over the past 5 years, Spero Therapeutics' median Change in Cash value was -$5.5 million (recorded in 2021), while the average stood at -$1.9 million.
  • In the last 5 years, Spero Therapeutics' Change in Cash tumbled by 65975.49% in 2021 and then surged by 2143127.27% in 2022.
  • Over the past 5 years, Spero Therapeutics' Change in Cash (Quarter) stood at -$275000.0 in 2021, then surged by 21431.27% to $58.7 million in 2022, then tumbled by 129.82% to -$17.5 million in 2023, then tumbled by 33.78% to -$23.4 million in 2024, then soared by 174.45% to $17.4 million in 2025.
  • Its Change in Cash stands at $17.4 million for Q3 2025, versus -$17.7 million for Q2 2025 and -$4.0 million for Q1 2025.